These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26984148)

  • 1. Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection.
    Moqueet N; Cooper C; Gill J; Hull M; Platt RW; Klein MB;
    J Infect Dis; 2016 Jul; 214(1):80-6. PubMed ID: 26984148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.
    Rollet-Kurhajec KC; Moodie EE; Walmsley S; Cooper C; Pick N; Klein MB;
    PLoS One; 2015; 10(6):e0129868. PubMed ID: 26090666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
    Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study.
    Martel-Laferrière V; Nitulescu R; Cox J; Cooper C; Tyndall M; Rouleau D; Walmsley S; Wong L; Klein MB;
    BMC Infect Dis; 2017 Jan; 17(1):80. PubMed ID: 28095797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals.
    Moqueet N; Infante-Rivard C; Platt RW; Young J; Cooper C; Hull M; Walmsley S; Klein MB;
    Int J Mol Sci; 2015 Mar; 16(3):6496-512. PubMed ID: 25803108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
    Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
    Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
    Bailey H; Nizova N; Martsynovska V; Volokha A; Malyuta R; Cortina-Borja M; Thorne C;
    BMC Infect Dis; 2016 Dec; 16(1):755. PubMed ID: 27955711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    Griesbeck M; Valantin MA; Lacombe K; Samri-Hassimi A; Bottero J; Blanc C; Sbihi Z; Zoorob R; Katlama C; Guiguet M; Altfeld M; Autran B;
    AIDS; 2017 Jun; 31(9):1223-1234. PubMed ID: 28492391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients.
    Cooper C; Rollet-Kurhajec KC; Young J; Vasquez C; Tyndall M; Gill J; Pick N; Walmsley S; Klein MB;
    HIV Med; 2015 Jan; 16(1):24-31. PubMed ID: 24837567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.
    McGovern BH; Birch C; Zaman MT; Bica I; Stone D; Quirk JR; Davis B; Zachary K; Basgoz N; Graeme-Cook F; Gandhi RT
    Clin Infect Dis; 2007 Nov; 45(10):1386-92. PubMed ID: 17968840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection.
    Moqueet N; Kanagaratham C; Gill MJ; Hull M; Walmsley S; Radzioch D; Saeed S; Platt RW; Klein MB;
    PLoS One; 2017; 12(5):e0176282. PubMed ID: 28467457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).
    Nguyen Truong T; Laureillard D; Lacombe K; Duong Thi H; Pham Thi Hanh P; Truong Thi Xuan L; Chu Thi N; Luong Que A; Vu Hai V; Nagot N; Tuaillon E; Dominguez S; Lemoine M
    PLoS One; 2016; 11(5):e0153744. PubMed ID: 27148964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
    Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
    Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
    J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
    Reiberger T; Payer BA; Ferlitsch A; Sieghart W; Breitenecker F; Aichelburg MC; Schmied B; Rieger A; Trauner M; Peck-Radosavljevic M;
    Antivir Ther; 2012; 17(7):1327-34. PubMed ID: 22948263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.
    Berenguer J; Rodríguez E; Miralles P; Von Wichmann MA; López-Aldeguer J; Mallolas J; Galindo MJ; Van Den Eynde E; Téllez MJ; Quereda C; Jou A; Sanz J; Barros C; Santos I; Pulido F; Guardiola JM; Ortega E; Rubio R; Jusdado JJ; Montes ML; Gaspar G; Esteban H; Bellón JM; González-García J;
    Clin Infect Dis; 2012 Sep; 55(5):728-36. PubMed ID: 22610932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
    Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
    Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.